<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946969</url>
  </required_header>
  <id_info>
    <org_study_id>KEEP-G 03</org_study_id>
    <nct_id>NCT03946969</nct_id>
  </id_info>
  <brief_title>Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer</brief_title>
  <official_title>Safety and Efficacy of Combination of Sintilimab and Platinum-based Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer: An Open-lable, Single-arm, Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the safety and efficacy of sintilimab combined with&#xD;
      platinum-based chemotherapy in neoadjuvant treatment of potentially resectable esophageal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as an open-lable, single-arm, exploratory clinical study. Sintilimab&#xD;
      in combination with liposome paclitaxel, cis-platinum and S-1 will be given every 3 weeks to&#xD;
      our patients for 2 cycles as neoadjuvant therapy. A radical dissection is scheduled within 6&#xD;
      weeks after last neoadjuvant treatment. This study will be devided for 3 phases: safety&#xD;
      run-in, efficacy pilot and efficacy confirmation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>20 months</time_frame>
    <description>From the day of neoadjuvant therapy to 30 days after surgery or within 90 days after last neoadjuvant treatment. To evaluate the incidence of TEAE, rate of grade 3 and 4 TEAE (CTCAE 5.0), rate of surgery delay over 30 days and/or inoperable patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Pathological Response (MPR) rate</measure>
    <time_frame>20 months</time_frame>
    <description>MPR is defined as 10% or fewer viable cancer cells in the hematoxylin and eosin (H&amp;E)-stained slides from the resected tumor following neoadjuvant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 Resection</measure>
    <time_frame>20 months</time_frame>
    <description>R0 resection means that following surgery, no cancer cells are seen microscopically at the resection margin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>20 months</time_frame>
    <description>Objective response rate is defined as the rate of patients with at least a 30% decrease in the sum of the LD (longest diameter) of target lesions, which include complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>From from surgery to the date of recurrence or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the begin of neoadjuvant treatment until the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab + Liposome Paclitaxel + Cis-Platinum + S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab 200mg ivd d1, repeated every 3 weeks for two cycles.</description>
    <arm_group_label>Sintilimab + Liposome Paclitaxel + Cis-Platinum + S-1</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Paclitaxel + Cisplatin + S-1</intervention_name>
    <description>Liposomal Paclitaxel 135mg/m2 ivd d1 + Cisplatin 25mg/m2 ivd d1-3 + S-1 40mg capsule po d1-14, repeated every 3 weeks for two cycles.</description>
    <arm_group_label>Sintilimab + Liposome Paclitaxel + Cis-Platinum + S-1</arm_group_label>
    <other_name>PFC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically or cytologically confirmed esophageal squamous cell carcinoma.&#xD;
&#xD;
        The tumor is located in the middle or lower third of the esophagus ( more than 18cm below&#xD;
        incisor), potentially resectable and requiring neoadjuvant therapy (T1b-3, N0/N+, M0 or&#xD;
        T4a, N0-1, M0).&#xD;
&#xD;
        No prior treatment for this disease.&#xD;
&#xD;
        Eastern cooperative oncology group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
        Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory&#xD;
        required by protocol.&#xD;
&#xD;
        Understand and voluntarily sign the informed consent(s).&#xD;
&#xD;
        Patients who are able to complete the treatment and follow-up according to the study plan.&#xD;
&#xD;
        Patients who have sufficient tissue samples and agree to provide their tissue samples and&#xD;
        blood samples for detailed analysis.&#xD;
&#xD;
        Female patients in child bearing period must have evidence of negative pregnancy test and&#xD;
        agree to take effective contraceptive measures during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who may develop tracheoesophageal fistula or aortoesophageal fistula.&#xD;
&#xD;
        Patients suffering from severe malnutrition or needing tube feeding.&#xD;
&#xD;
        Uncured patients with other malignancies within 2 years.&#xD;
&#xD;
        Patients who have active autoimmune diseases or patients who are undergoing treatment of&#xD;
        autoimmune diseases.&#xD;
&#xD;
        Patients who need systemic glucocorticosteroid treatment (more than 10mg prednisone daily&#xD;
        or other equivalent drugs) within 7 days before the neoadjuvant therapy or other&#xD;
        immunosuppressive drugs.&#xD;
&#xD;
        Patients who have immune deficiency.&#xD;
&#xD;
        Patients with active viral or bacterial infection who need systemic treatment within 7 days&#xD;
        before the neoadjuvant therapy.&#xD;
&#xD;
        Patients with uncontrolled diabetes mellitus.&#xD;
&#xD;
        Patients with interstitial pulmonary disease, noninfectious pneumonia, or pulmonary&#xD;
        fibrosis.&#xD;
&#xD;
        Patients with preexisting symptoms of sensory or motor nerve damage (greater than Grade 1,&#xD;
        WHO) .&#xD;
&#xD;
        Patients who have received allogeneic organ or stem cell transplants.&#xD;
&#xD;
        Patients who are allergic to drugs or related ingredients in this study.&#xD;
&#xD;
        Patients who take part in clinical trials of other drugs or biological therapy at present.&#xD;
&#xD;
        Patients with any serious or unstable medical condition or mental illness.&#xD;
&#xD;
        Patients who are dependent on or addicted to alcohol or drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhong Gu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Gu Yanhong</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

